Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma.

Chinese medical journal - 20 Jan 2010

Zhang Wei, Wang Xuan, Li Jian, Duan Ming-hui, Zhou Dao-bin

Abstract excerpt

BACKGROUND: Rituximab is used extensively in combination with chemotherapy to cure non-Hodgkin's lymphoma (NHL), and not only accelerates short-term improvement, but also prolongs patient survival and decreases receptor relapse. The aim of this study was to evaluate the impact of Fcgamma IIIA (FcgammaRIIIA) gene polymorphisms on the response to rituximab therapy for newly diagnosed B-cell lymphomas. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Asian People

Share to Lymphoma, Large B-Cell, Diffuse

Share to Receptors, IgG

Share to Rituximab

Share to Young Adult

Source

Identifiers

PMID: 20137370

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma.PMID 20137370Read ↗

[Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study].Semantic proximity Read ↗

The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.Semantic proximity Read ↗

FCGR3A polymorphism : It is helpful for the management of diffuse large B-cell lymphomaSemantic proximity Read ↗

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Semantic proximity Read ↗

Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol.Semantic proximity Read ↗

Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis.Semantic proximity Read ↗

Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.Semantic proximity Read ↗

[Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].Semantic proximity Read ↗

FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.Semantic proximity Read ↗

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.Semantic proximity Read ↗

Comprehensive genetic and functional analysis of FcγRs in rituximab therapy for autoimmunity reveals a key role for FcγRIIIa on NK cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.